Shanghai Kaibao Pharmaceutical Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000JZ3
CNY
6.52
0.05 (0.77%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
1,450.56
1,570.13
1,101.94
1,089.08
899.81
1,407.78
1,486.43
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,450.56
1,570.13
1,101.94
1,089.08
899.81
1,407.78
1,486.43
Raw Material Cost
294.09
330.21
259.72
246.82
186.00
258.63
274.43
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
214.31
0.00
0.00
226.18
166.54
223.25
212.89
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.15
0.12
0.13
0.29
0.77
0.00
0.29
Selling and Distribution Expenses
710.97
846.35
613.35
649.72
574.92
821.50
874.82
Other Expenses
-12.42
8.45
4.70
-15.26
-10.82
-16.87
-16.58
Total Expenditure (Excl Depreciation)
1,095.34
1,261.16
920.19
970.44
820.04
1,134.70
1,196.60
Operating Profit (PBDIT) excl Other Income
355.20000000000005
309
181.70000000000002
118.6
79.80000000000001
273.09999999999997
289.8
Other Income
80.84
92.25
59.90
53.39
65.44
46.60
41.45
Operating Profit (PBDIT)
469.58
439.53
273.09
206.71
185.54
367.22
379.54
Interest
0.15
0.12
0.13
0.29
0.77
0.00
0.29
Exceptional Items
1.10
-13.68
-6.09
-2.91
-12.14
-17.67
-53.21
Gross Profit (PBDT)
1,156.47
1,239.92
842.21
842.27
713.81
1,149.15
1,212.00
Depreciation
36.35
37.64
31.72
33.86
41.02
48.34
48.10
Profit Before Tax
434.18
388.08
235.15
169.65
131.60
301.21
277.94
Tax
59.27
56.63
36.11
29.54
25.48
50.22
47.89
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
375.58
327.87
190.80
140.11
106.12
250.99
226.81
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
375.58
327.87
190.80
140.11
106.12
250.99
226.81
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-0.67
-0.97
-0.72
-0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
374.91
326.90
190.08
140.11
106.12
250.99
226.81
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
0.0
Reserves
4,102.05
4,031.22
3,761.75
3,044.91
2,578.32
2,569.49
2,495.93
Earnings per share (EPS)
0.36
0.31
0.18
0.13
0.1
0.24
0.0
Diluted Earnings per share
0.36
0.31
0.18
0.13
0.1
0.24
0.0
Operating Profit Margin (Excl OI)
24.29%
19.72%
16.47%
10.97%
8.79%
19.34%
19.51%
Gross Profit Margin
32.44%
27.11%
24.22%
18.69%
19.18%
24.83%
21.93%
PAT Margin
25.89%
20.88%
17.32%
12.87%
11.79%
17.83%
15.26%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is -7.61% vs 42.49% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 14.68% vs 71.96% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 11.92% vs 62.90% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Shanghai Kaibao Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
1,450.56
0
1,450.56
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,450.56
0
1,450.56
Raw Material Cost
294.09
0
294.09
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
214.31
0
214.31
Power Cost
0
0
0.00
Manufacturing Expenses
0.15
0
0.15
Selling and Distribution Expenses
710.97
0
710.97
Other Expenses
-12.42
0.00
-12.42
Total Expenditure (Excl Depreciation)
1,095.34
0
1,095.34
Operating Profit (PBDIT) excl Other Income
355.22
0.00
355.22
Other Income
80.84
0
80.84
Operating Profit (PBDIT)
469.58
0
469.58
Interest
0.15
0
0.15
Exceptional Items
1.10
0
1.10
Gross Profit (PBDT)
1,156.47
0
1,156.47
Depreciation
36.35
0
36.35
Profit Before Tax
434.18
0
434.18
Tax
59.27
0
59.27
Provisions and contingencies
0
0
0.00
Profit After Tax
375.58
0
375.58
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
375.58
0
375.58
Share in Profit of Associates
0
0
0.00
Minority Interest
-0.67
0
-0.67
Other related items
0.00
0.00
0.00
Consolidated Net Profit
374.91
0
374.91
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
4,102.05
0
4,102.05
Earnings per share (EPS)
0.36
0
0.36
Diluted Earnings per share
0.36
0
0.36
Operating Profit Margin (Excl OI)
24.29%
0%
0.00
24.29%
Gross Profit Margin
32.44%
0%
0.00
32.44%
PAT Margin
25.89%
0%
0.00
25.89%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 145.06 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -7.61% vs 42.49% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 37.49 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 14.68% vs 71.96% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 38.87 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 11.92% vs 62.90% in Dec 2023

Annual - Interest
Interest 0.01 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 24.29%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023